Supportive Care in Cancer https://doi.org/10.1007/s00520-018-4301-3 LETTER TO THE EDITOR Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? Kadri Altundag Received: 17 February 2018 /Accepted: 27 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 To the Editor, rates of MRONJ in both control and study arms were I wish to congratulate van Cann and their colleagues in almost similar (10.9 vs. 11.1%, p = 0.95) in the longer which they investigated medication-related osteonecrosis follow-up. of the jaw (MRONJ) incidence in patients exposed con- comitantly to bone resorption inhibitors (BRIs) and vas- Compliance with ethical standards cular endothelial growth factor receptor tyrosine kinase Conflict of interest The author has no conflict of interest. inhibitors (VEGFR-TKIs). They concluded that patients receiving concomitant treatment with VEGFR-TKIs and BRIs have a five to ten times higher risk for development of MRONJ compared to patients treated with BRIs alone. Reference However, 86.7 and of 1.9% of all patients in study group (BRIs + VEGFR-TKIs) and control groups (BRIs only) 1. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems were diagnosed with renal cell carcinoma, respectively. L et al (2018) Incidence of medication-related osteonecrosis of the Therefore, it is not generalizable to conclude that concom- jaw in patients treated with both bone resorption inhibitors and vas- itant treatment with VEGFR-TKIs and BRIs increase cular endothelial growth factor receptor tyrosine kinase inhibitors. MRONJ incidence in all solid tumors. Actually, incidence Support Care Cancer 26(3):869–878 * Kadri Altundag email@example.com MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey
Supportive Care in Cancer – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera